Your browser doesn't support javascript.
loading
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study.
Di Giacomo, A M; Ascierto, P A; Queirolo, P; Pilla, L; Ridolfi, R; Santinami, M; Testori, A; Simeone, E; Guidoboni, M; Maurichi, A; Orgiano, L; Spadola, G; Del Vecchio, M; Danielli, R; Calabrò, L; Annesi, D; Giannarelli, D; Maccalli, C; Fonsatti, E; Parmiani, G; Maio, M.
Afiliación
  • Di Giacomo AM; Medical Oncology and Immunotherapy, University Hospital of Siena, Istituto Toscano Tumori, Siena.
  • Ascierto PA; Medical Oncology and Innovative Therapies, Fondazione 'G. Pascale', National Cancer Institute, Naples.
  • Queirolo P; Medical Oncology 2, IRCCS, AOU San Martino, Genoa.
  • Pilla L; Melanoma Unit, San Raffaele Scientific Institute, Milan.
  • Ridolfi R; Immunotherapy and Somatic Cell Therapy Unit, Scientific Institute of Romagna, Meldola.
  • Santinami M; Melanoma and Sarcoma Unit, National Institute for Cancer Research, Milan.
  • Testori A; Dermatoncological Division, Istituto Europeo di Oncologia, Milan.
  • Simeone E; Medical Oncology and Innovative Therapies, Fondazione 'G. Pascale', National Cancer Institute, Naples.
  • Guidoboni M; Immunotherapy and Somatic Cell Therapy Unit, Scientific Institute of Romagna, Meldola.
  • Maurichi A; Melanoma and Sarcoma Unit, National Institute for Cancer Research, Milan.
  • Orgiano L; Medical Oncology 2, IRCCS, AOU San Martino, Genoa.
  • Spadola G; Dermatoncological Division, Istituto Europeo di Oncologia, Milan.
  • Del Vecchio M; Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan.
  • Danielli R; Medical Oncology and Immunotherapy, University Hospital of Siena, Istituto Toscano Tumori, Siena.
  • Calabrò L; Medical Oncology and Immunotherapy, University Hospital of Siena, Istituto Toscano Tumori, Siena.
  • Annesi D; Medical Oncology and Immunotherapy, University Hospital of Siena, Istituto Toscano Tumori, Siena.
  • Giannarelli D; Statistical Unit, Regina Elena National Cancer Institute, Rome.
  • Maccalli C; Medical Oncology and Immunotherapy, University Hospital of Siena, Istituto Toscano Tumori, Siena; Italian Network for Tumor Biotherapy (NIBIT), Siena, Italy.
  • Fonsatti E; Medical Oncology and Immunotherapy, University Hospital of Siena, Istituto Toscano Tumori, Siena.
  • Parmiani G; Melanoma Unit, San Raffaele Scientific Institute, Milan.
  • Maio M; Medical Oncology and Immunotherapy, University Hospital of Siena, Istituto Toscano Tumori, Siena. Electronic address: mmaiocro@gmail.com.
Ann Oncol ; 26(4): 798-803, 2015 Apr.
Article en En | MEDLINE | ID: mdl-25538176
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Terapia Biológica / Neoplasias Encefálicas / Protocolos de Quimioterapia Combinada Antineoplásica / Melanoma Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2015 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Terapia Biológica / Neoplasias Encefálicas / Protocolos de Quimioterapia Combinada Antineoplásica / Melanoma Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2015 Tipo del documento: Article